Oncology research, biotechnology innovation, and cancer therapeutics by Verastem
Verastem, Inc. initiates first dosing in Phase 2 trial for KRAS G12D pancreatic cancer therapy
Verastem, Inc. has announced the first patient dosing in its TARGET-D 201 Phase 2 registration-directed trial. The study focuses on evaluating VS-7375, an investigational oral inhibitor targeting ...
Verastem, Inc. plans conference to unveil progress on KRAS G12D trial
Verastem, Inc. announced its plan to host an investor conference call and webcast to present progress and updated preliminary data from its Phase 1/2 TARGET-D 101 study. The trial focuses on the ...
Verastem, Inc. receives U.S. FDA fast track for KRAS G12D inhibitor in NSCLC treatment
Verastem, Inc. announced that the U.S. FDA has granted Fast Track designation for its investigational oral KRAS G12D (ON/OFF) inhibitor, VS-7375, intended for the treatment of KRAS G12D-mutated ...
Verastem, Inc. drives patient-focused efforts in rare ovarian cancer awareness
Verastem, Inc. is intensifying efforts to incorporate patient stories into research and understanding of ovarian cancer, with a particular emphasis on the rare low-grade serous ovarian cancer ...
Verastem, Inc. posts first quarter 2026 earnings, updates on RAS MAPK pathway pipeline
Verastem, Inc. released its financial results for the first quarter of 2026 and provided updates on its business operations. The company highlighted progress with its launch activities and ...
KRAS-mutated LGSOC campaign debuts as Verastem, Inc. targets patient support
Verastem, Inc. has announced the launch of the Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign to raise awareness around the first and only FDA-approved treatment specifically ...
Verastem, Inc. sets first quarter earnings call for May 7 at 4:30pm ET
Verastem, Inc. announced it will host its first quarter earnings call on Thursday, May 7, 2026, at 4:30pm ET. The company plans to present its financial results and provide updates on recent ...
AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor
Verastem, Inc. has announced the presentation of preclinical results for its investigational oral KRAS G12D (ON/OFF) inhibitor, VS-7375, at this year's AACR Meeting. The company claims VS-7375 ...
Verastem, Inc. releases Q4 and year end 2025 results with business update
Verastem, Inc. has announced its fourth quarter and year end 2025 financial results along with updates on its business operations. The company also shared insights into the progress of its ...
